Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia

Atherosclerosis

Volumn 171, Issue 2, 2003, Pages 273-279

  Raal, Frederick J ^a   Marais, A David ^b   Klepack, Ellen ^c   Lovalvo, Jennifer ^c   McLain, Richard ^c   Heinonen, Therese ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c PFIZER INC   (United States)

Author keywords

ACAT inhibitor; Atorvastatin; Avasimibe; Homozygous familial hypercholesterolemia; Lipid lowering

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIBE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ARTICLE; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEADACHE; HOMOZYGOSITY; HUMAN; LIPID ANALYSIS; MALE; MONOTHERAPY; MUSCLE HYPERTONIA; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TENDON DISEASE; XANTHOMATOSIS;

EID: 0344896639     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.07.011     Document Type: Article

References (24)

1. Hobbs H.H., Russell D.W., Brown M.S., Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu. Rev. Genet. 24:1990;133-170.
2. Hobbs H.H., Brown M.S., Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1:1992;445-466.
3. Haitas B., Baker S.G., Meyer T.E., Joffe B.I., Seflel H.C. Natural history and cardiac manifestations of homozygous familial hypercholesterolemia. Q. J. Med. 76:1990;731-740.
4. Raal F.J., Pappu A., Illingworth D., Pilcher G., Marais A.D., Firth J. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 150:2000;421-428.
5. Raal F.J., Pilcher G.J., Illingworth D.R., Pappu A., Stein E., Laskarzewski P. Expanded dose Simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis. 135:1997;249-256.
6. Marais A.D., Naoumova R.P., Firth J.C. Decreased production of low density lipoprotein by atorvastatin in homozygous familial hypercholesterolemia. J. Lipid Res. 38:1997;2071-2078.
7. Burnett J.R., Wilcox L.J., Huff M.W. Acyl-coenzyme A:cholesterol acyltransferase and hepatic apolipoprotein B secretion. Clin. Chim. Acta. 286(1-2):1999;231-242.
8. Kinneunen P.M., De Michele A., Lange L.G. Chemical modification of acyl-CoA-cholesterol acyltransferase sub-types by differential diethyl pyrocarbonate sensitivity. Biochemistry. 27:1998;7344-7350.
9. Anderson R.A., Joyce C., Davis M., Reagan J., Clark M., Shelness G., et al. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J. Biol. Chem. 273(4):1998;26747- 26754.
10. Krause B, Bocan TM, Inflammation mediators and pathways. In: Ruffolo Jr R, Hollinger M, editors. ACAT inhibitors, physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals, New York: CRC Press;1995. p. 173-91.
11. Joyce C., Skinner K., Anderson R.A., Rudel L.L. Acyl-coenzyme A: cholesterol acyltransferase. Curr. Opin. Lipidol. 10(2):1999;89-95.
12. Lee H.T., Sliskovic D.R., Picard J.A., Roth B., Wierenja W., Hicks J., et al. Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J. Med. Chem. 39:1996;5031-5034.
13. Delsing D.J.M., Offerman E.H., Van der Boom H., Van Duyvenvoorde W., Havekes L.M., Princen H.M.G. The acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor avasimibe reduces atherosclerosis independently of its lipid-lowering effect in cholesterol-fed apoE3-Leiden transgenic mice. Circulation. 100:1999;I613. [abstract].
14. Bocan T.M.A., Krause B.R., Rosebury W.S., Mueller S.B., Lu X., Dagle C., et al. The ACAT inhibitor, avasimibe, reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Atherioscler Thromb. Vasc. Biol. 20:2000;70-79.
15. Nicolosi R.J., Wilson T.A., Krause B.R. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis. 137:1998;77-85.
16. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
17. Remmell P.S., Gorder D.D., Hall Y., Tillotson J.L. Assessing dietary adherence in multiple risk factor intervention trial (MRFIT). I. Use of dietary monitoring tool. J. Am. Diet. Assoc. 76:1980;351-356.
18. Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The centers for disease control national heart, lung, and blood institute lipid standardization program: an approach to accurate and precise lipid measurements. Clin. Lab. Med. 9:1989;105-135.
19. Steiner PM, Freidel J, Breminer WF, Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinic's methodology. J. Clin. Chem. Clin. Biochem. 1981;19:850 [abstract].
20. Steel B.W., Koehler D.F., Azar M.M., Blaszkowski T.P., Kuba K., Dempsey M.E. Enzymatic determinations of cholesterol from high-density-lipoprotein fractions were prepared by a precipitation technique. Clin. Chem. 22:1976;98-101.
21. Murray L. Physicians Desk Reference, Montvale, NJ; Thomson PDR, 2003. p. 2610-13.
22. Insull W., Koren M., Davignon J., Sprecher D., Schrott H., Keilson L., et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 157:2001;137-144.
23. Wilcox L.J., Barrett P.H., Newton R.S. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of apoB. Arterioscler Thromb. Vasc. Biol. 19:1999;939-949.
24. Burnett J.R., Wilcox L.J., Telford D.E. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apoprotein B production in minature pigs. J. Lipid. Res. 40:1999;1317-1327.